Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BOLT · NASDAQ · Pharmaceutical Preparations
Bolt Biotherapeutics (BOLT) · oqro.io/stocks/BOLT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$6.08+0.17 (+2.88%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Institutions reporting a stake, Q2 2026
23
-1 vs Q1 2026
Share of stock reported
31.0%
597K of 1.93M shares outstanding
Change vs Q1 2026
-17K shares
2 new positions, 3 positions closed
Reported in 13F filings, which cover managers over $100M and include double counting. A 13F shows holdings on the last day of the quarter, not when shares were bought or sold. Change counts the 23 managers that reported both quarters.
Source: SEC Form 13F data sets, every filer, common stock only (options and bonds left out). Amendments are applied; lines whose value was filed in thousands are scaled, and lines whose shares and value disagree are left out.
